Zang, Li
Li, Yijun
Hao, Haojie
Liu, Jiejie
Cheng, Yu
Li, Bing
Yin, Yaqi
Zhang, Qian
Gao, Fei
Wang, Haibin
Gu, Shi
Li, Jia
Lin, Fengxiang
Zhu, Yingfei
Tian, Guanglei
Chen, Yulong
Gu, Weijun
Du, Jin
Chen, Kang
Guo, Qinghua
Yang, Guoqing
Pei, Yu
Yan, Wenhua
Wang, Xianling
Meng, Junhua
Zhang, Saichun
Ba, Jianming
Lyu, Zhaohui
Dou, Jingtao
Han, Weidong
Mu, Yiming http://orcid.org/0000-0002-3344-3540
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial
https://doi.org/10.1186/s13287-022-02848-6
Funding for this research was provided by:
National Natural Science Foundation of China (81700679, 81700680)
National Key Research and Development Program of China (2017YFC0908402)
863 Projects of the Ministry of Science and Technology of China (2013AA020105)
Article History
Received: 24 November 2021
Accepted: 14 April 2022
First Online: 3 May 2022
Declarations
:
: The study protocol was approved by the Ethical Committee of the First Medical Center of PLA General Hospital (Approval No. 2013-107-01) and conformed to the Declaration of Helsinki guidelines. All participants provided written informed consent before recruitment. This study was registered on ClinicalTrials.gov (Identifier: NCT02302599).
: Informed written consent was obtained from the patient for publication of this report.
: The authors declare that they have no competing interests.